{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:02:37Z","timestamp":1789574557479,"version":"build-2803163510"},"reference-count":17,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"\n Importance<\/jats:title>\n Merkel cell carcinoma (MCC) is associated with a high recurrence rate of 40%. It is important to know which of 2 blood-based tumor biomarkers available for use in clinical practice is more accurate in detecting MCC recurrence.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare the performance of circulating tumor DNA (ctDNA) and the MCC polyomavirus (MCPyV) oncoprotein antibody test for detecting MCC recurrence.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n In this multicenter cohort study across 3 US academic centers (Stanford, Dana-Farber Brigham, and University of Washington), patients with stage I-IV MCC underwent serial paired ctDNA and antibody testing for disease surveillance between April 2020 and March 2024. ctDNA was considered positive if mean tumor molecules per milliliter of plasma values were greater than 0.00, while a rising antibody test result was defined as a 30% or greater increase in titer. Inclusion criteria were clinically disease-free at baseline, detectable MCPyV antibodies at diagnosis, and both ctDNA and antibody tests performed within 45 days of each other in at least 1 time point per patient. Predictive performance for recurrence was assessed and compared between tests.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was clinical recurrence. Predictive performance measures for each test included positive (PPV), negative predictive value (NPV), and hazard ratios (HRs).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n In this study among 169 patients with 703 paired tests (median testing interval, 96 days; 109 males [64%]; 60 females [36%]), there were 36 clinical recurrences from 32 patients over a median follow-up of 483 days (IQR, 274-714 days). Compared with antibody testing, ctDNA had a significantly higher PPV at 365 days (73% [95% CI, 58%-85%] vs 52% [95% CI, 32%-71%];\n P<\/jats:italic>\n \u2009=\u2009.02), higher NPV at 90 days (99% [95% CI, 98.8%-100%] vs 97% [95% CI, 95%-98%];\n P<\/jats:italic>\n \u2009=\u2009.001), and a greater HR (HR, 47.9 [95% CI, 16.5-139.0] vs 7.3 [95% CI, 3.8-13.9]; HR ratio, 6.6 [95% CI, 2.5-41.0];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). Use of both ctDNA and antibody tests together identified only 1 additional recurrence compared with the use of ctDNA testing alone.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This study found that ctDNA was more accurate than MCPyV antibody testing in detecting recurrence of MCC. ctDNA appears to be a more reliable guide than the MCPyV antibody for surveillance practices and ongoing risk stratification in most patients with MCC.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamadermatol.2026.2153","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:30:25Z","timestamp":1783524625000},"page":"880","source":"Crossref","is-referenced-by-count":0,"title":["ctDNA or Merkel Virus Antibodies for Surveillance of Merkel Cell Carcinoma Recurrence"],"prefix":"10.1001","volume":"162","author":[{"given":"Manisha","family":"Thakuria","sequence":"first","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Akaike","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Washington, Seattle"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann W.","family":"Silk","sequence":"additional","affiliation":[{"name":"Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Hippe","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Y.","family":"Ch\u2019en","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Washington, Seattle"},{"name":"Albert Einstein College of Medicine, Bronx, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rian","family":"Alam","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Washington, Seattle"},{"name":"Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua E.","family":"Chan","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song Y.","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Washington, Seattle"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karam","family":"Khaddour","sequence":"additional","affiliation":[{"name":"Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate B.","family":"Biese","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin J.","family":"Jabbour","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macy W.","family":"Gilmour","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Finberg","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meliea W.","family":"Chiu","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Kim","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M.","family":"Urman","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan Thomas","family":"Hall","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington"},{"name":"Division of Hematology and Oncology, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailender","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington"},{"name":"Division of Hematology and Oncology, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Nghiem","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Washington, Seattle"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa C.","family":"Zaba","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"doi260025r1","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1001\/jamadermatol.2021.6096","article-title":"Recurrence and mortality risk of Merkel cell carcinoma by cancer stage and time from diagnosis.","volume":"158","author":"McEvoy","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"12","key":"doi260025r3","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/s41571-018-0103-2","article-title":"The biology and treatment of Merkel cell carcinoma: current understanding and research priorities.","volume":"15","author":"Harms","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"doi260025r4","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1002\/ijc.24509","article-title":"Human Merkel cell polyomavirus infection II. MCV is a common human infection that can be detected by conformational capsid epitope immunoassays.","volume":"125","author":"Tolstov","year":"2009","journal-title":"Int J Cancer"},{"issue":"1","key":"doi260025r5","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02079-16","article-title":"Merkel cell polyomavirus exhibits dominant control of the tumor genome and transcriptome in virus-associated Merkel cell carcinoma.","volume":"8","author":"Starrett","year":"2017","journal-title":"mBio"},{"issue":"21","key":"doi260025r6","doi-asserted-by":"publisher","first-page":"8388","DOI":"10.1158\/0008-5472.CAN-10-2128","article-title":"Antibodies to Merkel cell polyomavirus T antigen oncoproteins reflect tumor burden in Merkel cell carcinoma patients.","volume":"70","author":"Paulson","year":"2010","journal-title":"Cancer Res"},{"issue":"11","key":"doi260025r7","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamadermatol.2025.3155","article-title":"Polyomavirus antibodies for Merkel cell carcinoma recurrence detection.","volume":"161","author":"Gunnell","year":"2025","journal-title":"JAMA Dermatol"},{"issue":"8","key":"doi260025r8","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1002\/cncr.30475","article-title":"Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: a prospective validation study.","volume":"123","author":"Paulson","year":"2017","journal-title":"Cancer"},{"issue":"15","key":"doi260025r9","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1002\/cncr.35314","article-title":"The prognostic value of the Merkel cell polyomavirus serum antibody test: a dual institutional observational study.","volume":"130","author":"Miller","year":"2024","journal-title":"Cancer"},{"issue":"26","key":"doi260025r10","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1200\/JCO.23.02054","article-title":"Circulating tumor DNA assay detects Merkel cell carcinoma recurrence, disease progression, and minimal residual disease: surveillance and prognostic implications.","volume":"42","author":"Akaike","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"doi260025r11","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1158\/2159-8290.CD-13-1014","article-title":"Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA.","volume":"4","author":"Haber","year":"2014","journal-title":"Cancer Discov"},{"issue":"3","key":"doi260025r12","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3390\/cancers15030609","article-title":"Evolving applications of circulating tumor DNA in Merkel cell carcinoma.","volume":"15","author":"Prakash","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"408","key":"doi260025r13","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1080\/01621459.1989.10478874","article-title":"The robust inference for the Cox proportional hazards model.","volume":"84","author":"Lin","year":"1989","journal-title":"J Am Stat Assoc"},{"issue":"2","key":"doi260025r14","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1177\/0013164416678980","article-title":"Using cluster bootstrapping to analyze nested data with a few clusters.","volume":"78","author":"Huang","year":"2018","journal-title":"Educ Psychol Meas"},{"issue":"4","key":"doi260025r15","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1214\/088342304000000396","article-title":"Permutation methods: a basis for exact inference.","volume":"19","author":"Ernst","year":"2004","journal-title":"Stat Sci"},{"issue":"1","key":"doi260025r16","doi-asserted-by":"publisher","DOI":"10.1177\/1073274818789355","article-title":"Immortal time bias in observational studies of time-to-event outcomes: assessing effects of postmastectomy radiation therapy using the National Cancer Database.","volume":"25","author":"Agarwal","year":"2018","journal-title":"Cancer Control"},{"issue":"2","key":"doi260025r17","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.jaad.2025.10.032","article-title":"Circulating tumor DNA level is associated with time to clinical recurrence in Merkel cell carcinoma: implications for patient management.","volume":"94","author":"Akaike","year":"2026","journal-title":"J Am Acad Dermatol"},{"key":"doi260025r2","unstructured":"National Comprehensive Cancer Network (NCCN). Merkel cell carcinoma (version 2.2025). Accessed May 30, 2025. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1444"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2851488\/jamadermatology_thakuria_2026_oi_260025_1788201952.68696.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T15:03:24Z","timestamp":1789571004000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2851488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":17,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2026.2153","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}